Biotech Values

[north40000]

AMLN/NVO: Exenatide-once-weekly and liraglutide

I assume you are aware that LLY/AMLN will compare the above 2 drugs in a head to head comparison announced here, NCT01029886 at ClinicalTrials.gov:

http://investorvillage.com/smbd.asp?mb=2885&mn=63311&pt=msg&mid=8299768

Perhaps answers to your questions will ensue as a result of the study, if not before. Or perhaps either of us could call LLY or AMLN to obtain the answers you want.

I have to hand it to AMLN/LLY. It appears they plan to take NVO head on.

"No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose."